Jevtana
Generic Name
Cabazitaxel
Manufacturer
Sanofi
Country
France
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| jevtana 60 mg injection | ৳ 142,687.22 | N/A |
Description
Overview of the medicine
Jevtana (cabazitaxel) is an anti-cancer medication used to treat metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel-containing regimen. It belongs to a class of drugs called taxanes, which work by interfering with the growth of cancer cells.
Uses & Indications
Dosage
Adults
25 mg/m² administered as a 1-hour intravenous infusion every 3 weeks. Premedication with antihistamines, corticosteroids, and H2 blockers is required.
Elderly
No specific dose adjustment is required for elderly patients based on age alone, but caution and close monitoring are advised due to potential age-related comorbidities and reduced organ function.
Renal_impairment
No dose adjustment for mild to moderate renal impairment. Data limited for severe renal impairment; use with caution.
How to Take
For intravenous infusion only, after dilution with the supplied diluent and further dilution with a compatible infusion solution (e.g., 0.9% sodium chloride or 5% dextrose). Must be administered through a dedicated infusion line or a multi-lumen port. Premedication is crucial to prevent hypersensitivity reactions.
Mechanism of Action
Cabazitaxel binds to tubulin and stabilizes microtubules, leading to inhibition of mitotic cell division and ultimately apoptosis of cancer cells. This prevents cancer cell proliferation.
Pharmacokinetics
Onset
Rapid (systemic exposure achieved during infusion).
Excretion
Mainly fecal (approximately 80%), with a small amount excreted renally (approximately 3.7%).
Half life
Approximately 80-90 hours (terminal half-life).
Absorption
Administered intravenously, hence 100% bioavailability.
Metabolism
Primarily hepatic, via CYP3A4 and to a lesser extent CYP2C8.
Side Effects
Contraindications
- Hypersensitivity to cabazitaxel, other taxanes, or any components of the formulation.
- Neutrophil counts ≤ 1,500 cells/mm³.
- Severe hepatic impairment (Child-Pugh Class B or C).
Drug Interactions
Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin)
May decrease cabazitaxel plasma concentrations; concomitant use should be avoided as it may reduce efficacy.
Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir)
May increase cabazitaxel plasma concentrations; concomitant use should be avoided or dose adjusted with careful monitoring if unavoidable.
Storage
Store unopened vials in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light. Do not freeze. After dilution, the solution should be used immediately.
Overdose
No specific antidote is known for cabazitaxel overdose. Management of overdose should involve supportive care, including close monitoring of hematological parameters (especially neutropenia) and appropriate symptomatic treatment.
Pregnancy & Lactation
Not recommended for use during pregnancy; advise women of childbearing potential to use effective contraception during treatment and for at least 6 months after the last dose. Avoid breastfeeding during treatment and for at least 1 week after the last dose.
Side Effects
Contraindications
- Hypersensitivity to cabazitaxel, other taxanes, or any components of the formulation.
- Neutrophil counts ≤ 1,500 cells/mm³.
- Severe hepatic impairment (Child-Pugh Class B or C).
Drug Interactions
Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin)
May decrease cabazitaxel plasma concentrations; concomitant use should be avoided as it may reduce efficacy.
Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir)
May increase cabazitaxel plasma concentrations; concomitant use should be avoided or dose adjusted with careful monitoring if unavoidable.
Storage
Store unopened vials in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light. Do not freeze. After dilution, the solution should be used immediately.
Overdose
No specific antidote is known for cabazitaxel overdose. Management of overdose should involve supportive care, including close monitoring of hematological parameters (especially neutropenia) and appropriate symptomatic treatment.
Pregnancy & Lactation
Not recommended for use during pregnancy; advise women of childbearing potential to use effective contraception during treatment and for at least 6 months after the last dose. Avoid breastfeeding during treatment and for at least 1 week after the last dose.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
36 months when stored unopened at recommended conditions.
Availability
Hospitals, specialized cancer treatment centers
Approval Status
FDA Approved
Patent Status
Patent protected (Sanofi)
Clinical Trials
Clinical trials, such as TROPIC and CARD, have demonstrated Jevtana's efficacy in improving overall survival in patients with metastatic castration-resistant prostate cancer who have progressed after docetaxel-based chemotherapy.
Lab Monitoring
- Complete blood counts (CBC) including neutrophil count (before each cycle and as needed).
- Liver function tests (baseline and periodically).
- Kidney function tests (baseline and periodically).
- Monitor for signs and symptoms of neuropathy.
Doctor Notes
- Prior to administration, ensure the patient has an absolute neutrophil count (ANC) of at least 1,500 cells/mm³.
- Strictly follow premedication protocol to mitigate hypersensitivity reactions and manage myelosuppression with appropriate dose modifications.
- Monitor for signs of neuropathy, fluid retention, and gastrointestinal toxicity regularly.
Patient Guidelines
- Report any signs of infection (fever, chills, sore throat) immediately to your healthcare provider.
- Be aware of potential neurological side effects like numbness, tingling, or weakness in hands/feet.
- Maintain good hydration and strictly follow all instructions for premedication before each infusion.
- Do not take any new medications, including over-the-counter drugs, herbal remedies, or supplements, without consulting your doctor.
Missed Dose Advice
Consult your doctor or healthcare provider immediately if a dose is missed. Do not double the dose to compensate for a missed one. The healthcare team will decide on the next steps.
Driving Precautions
Jevtana may cause fatigue, dizziness, or vision disturbances. Patients should be advised not to drive or operate machinery if they experience these symptoms, or until they know how the medication affects them.
Lifestyle Advice
- Maintain good personal hygiene to reduce the risk of infection, especially during periods of low white blood cell counts.
- Avoid contact with people who are sick or have infections.
- Discuss with your doctor about any physical activities or dietary restrictions during treatment.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.